Laxatives Market Research Report - Forecast till 2032

Laxatives Market Research Report Information By Route of Administration (Oral and Rectal), By Indication (Chronic Constipation, Irritable Bowel Syndrome, and Others), By Drug Type (Hyperosmotic, Bulk-Forming, Stool Softeners, Lubricants, and Stimulants), By End User (Hospitals & Clinics, Research Institutes, and Others) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032.

ID: MRFR/Pharma/2055-HCR | 85 Pages | Author: Rahul Gotadki | March 2024         

Laxatives Market Speak to Analyst Request a Free Sample

Global Laxatives Market Overview


The  laxatives market size was valued at USD 6.5 Billion in 2022. The Laxatives market industry is projected to grow from USD 6.89 Billion in 2023 to USD 10.98 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.00% during the forecast period (2023 - 2032). The rising number of research and development activities, the rise in the prevalence of constipation among various people and an increase in the investment for developing advanced technologies are the key market drivers enhancing market growth.


Laxatives Market


Source Secondary Research, Primary Research, MRFR Database and Analyst Review


Laxatives Market Trends


The increasing prevalence of eating disorders is driving the market growth


Market CAGR for laxatives is being driven by the increasing prevalence of eating disorders will fuel industry growth. Eating disorders have increased in developed economies such as the United States, the United Kingdom, Australia, and Germany. Overuse of laxatives is particularly common among patients with eating disorders. Laxatives, available over-the-counter (OTC), have also contributed to excessive use. The laxatives market is growing tremendously as a result of this abuse. The growing geriatric population is anticipated to enhance the market's growth rate. Bowel disorders are becoming more common as the population ages. This is due to their bodies' inability to adequately digest meals. Muscle suppleness loss and poor function can lead to major problems. As a result of these factors, senior citizens are increasingly using laxatives.


Additionally, the geriatric population is expected to significantly impact the market studied, as people over 65 are more prone to chronic diseases. Geriatric people are five times more prone than younger adults to experience constipation-related issues. A poor diet causes this, a lack of sufficient fluids, a lack of exercise, the use of specific medications to treat other medical disorders, and unfavorable bowel habits are a few causes of this inclination. As per the World Health Organization Facts of 2021, the proportion of the world population aged 60 and up will almost double from 12% to 22% between 2015 and 2050. Furthermore, according to the World Health Organization, by 2030, 1 out of every 6 people will be 60 years old or older. The number of people aged 60 and up is expected to enhance from 1 billion in 2020 to 1.4 billion by 2050. Thus, the growing geriatric population is expected to boost the laxatives market revenue.


High R&D spending for the development of innovative drugs, improvements in healthcare infrastructure, an increase in the elderly and geriatric population, sedentary lifestyles, changing dietary habits, and insufficient consumption of fast food in large quantities are all leading to increased demand for constipation treatment in the coming years. With the increased complexity of the healthcare industry, improved treatment and answers to emerging difficulties are required. Laxatives growth has been revolutionized by healthcare professionals with superior knowledge and expertise, the high prevalence of IBS, chronic constipation, and the development of cutting-edge drugs and treatment procedures.


Constipation is a common disorder experienced by every individual and is evident in 8% to 32.5% of the population worldwide. The increasing geriatric population, sedentary lifestyle and changing dietary habits in developed as well as upcoming economies and thus creating lucrative markets, especially the unexplored markets in the developing economies, is expected to increase the demand for constipation treatment across the globe in the near future. More than 50% of the people belonging to the age group above 50 years of age are prone to suffering chronic constipation. The average prevalence of constipation in adults has been around 16% worldwide, whereas 33.5% prevalence was seen in adults aged 60 to 110 years. There is a high prevalence of irritable bowel syndrome in emerging markets such as Asia Pacific and Latin America, leading to tremendous market growth over the forecast period.


Laxatives Market Segment Insights


Laxatives Route of Administration Insights


The  laxatives market segmentation, based on type, includes oral and rectal. The oral segment dominated the market, accounting for 35% of market revenue (2.41 Billion). In developing economies, category growth is driven by the growing prevalence of constipation among infants. However, rectal is the fastest-growing category due to the presence of a strong pipeline.


Laxatives Indication Insights


The  laxatives market segmentation, based on indication, includes chronic constipation, irritable bowel syndrome, and others. The chronic constipation category generated the most income (70.4%). Disorders such as diverticulosis cause constipation as a side effect. People become constipated due to the unusual foods they eat, contaminated foods, and other items. However, irritable bowel syndrome is the fastest-growing category, creating many opportunities for pharmaceutical companies.


Laxatives Drug Type Insights


The  laxatives market segmentation, based on drug type, includes hyperosmotic, bulk-forming, stool softeners, lubricants, and stimulants. The lubricants category generated the most income owing to the rising demand for bio-based lubricants. However, irritable bowel syndrome is the fastest-growing category owing to the approval of the expanded version of stimulant drugs as the adequate treatment that operates in 70% - 80% of the cases.


Laxatives End User Insights


The  laxatives market segmentation, based on end users, includes hospitals & clinics, research institutes, and others. The research institutes category generated the most income due to growing research and development activities in laxatives drugs. However, hospitals & clinics are the fastest-growing category, as surgery departments and operating rooms in hospitals & clinics have a wide variety of needs.


Figure 1  Laxatives Market by End User, 2022 & 2032 (USD Billion)
Laxatives Market by End User, 2022 & 2032


Source Secondary Research, Primary Research, MRFR Database and Analyst Review


Laxatives Regional Insights


By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American laxatives market will dominate owing to various government measures to reassure the usage of single-use medical supplies to prevent infections, and the presence of prominent market participants will boost the market growth in this region. Further, the US laxatives market held the largest market share, and the Canadian laxatives market was the fastest-growing market in the North American region.


Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.


Figure 2  LAXATIVES MARKET SHARE BY REGION 2022 (USD Billion)
LAXATIVES MARKET SHARE BY REGION 2022


Source Secondary Research, Primary Research, MRFR Database and Analyst Review


Europe's laxatives market accounts for the second-largest market share due to the growing number of individuals suffering from chronic constipation in this region. Further, the German laxatives market held the largest market share, and the UK laxatives market was the fastest-growing market in the European region.


The Asia-Pacific laxatives Market is expected to grow at the fastest CAGR from 2023 to 2032. This is due to the high adoption of advanced technology and the growing demand for minimally invasive procedures over conventional methods. Moreover, China’s laxatives market held the largest market share, and the Indian laxatives market was the fastest-growing market in the Asia-Pacific region.


Laxatives Key Market Players & Competitive Insights


Leading market players are investing heavily in research and development to expand their product lines, which will help the laxatives market grow even more. Market participants are also undertaking several strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the laxatives industry must offer cost-effective items.


Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the  laxatives industry to benefit clients and increase the market sector. Major players in the laxatives market, including F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Ireland), Sanofi (France), Pfizer Inc. (U.S.), and others, are attempting to increase market demand by investing in research and development operations.


Ardelyx Inc is a pharmaceutical company. It develops small molecule therapeutics for treating cardio-renal, gastrointestinal and metabolic disorders. The company offers products that include tenapanor and RDX013. Its products are utilized for hyperphosphatemia in patients with end-stage renal disease, constipation-predominant irritable bowel syndrome, and hyperkalemia in chronic kidney disease patients. Ardelyx develops proprietary drug discovery and design platforms to discover and design novel drug candidates, including Tenapanor. The firm collaborates with pharmaceutical and biotechnology enterprises to discover small-molecule drugs. In April 2022, Ardelyx, Inc. received the United States Food and Drug Administration for IBSRELA. This is an NHE3 inhibitor for treating irritable bowel syndrome with constipation (IBS-C) in adults.


Dabur India Ltd, a subsidiary of Burman Family Holdings, develops, markets and sells ayurvedic and natural healthcare products. The company’s product portfolio includes health supplements, digestives, cough and cold syrups and drops, energizers, women’s health and baby care products. It also offers hair oils, shampoos, moisturizing creams and lotions, toothpaste and toothpowders, room fresheners, fruit juices, beverages and other ethical products. Dabur markets its products under Vatika, Hajmola, Dabur Amla, Odonil and Odomos brand names. The company’s product range of merchandise is sold through organized retail chains, e-commerce platforms and specialized channels such as beauty retail and salons, chemists and ayurvedic pharmacies. In August 2019, Dabur announced that it had expanded the Ayurvedic laxative category with the 100% Ayurvedic product Dabur Kabz in India.


Key Companies in the Laxatives market include



  • Hoffmann-La Roche Ltd. (Switzerland)

  • Mylan N.V. (U.S.)

  • Teva Pharmaceutical Industries Ltd. (Ireland)

  • Sanofi (France)

  • Pfizer Inc. (U.S.)

  • GlaxoSmithKline plc (U.K.)

  • Novartis AG (Switzerland)

  • Merck & Co., Inc. (U.S.)

  • AstraZeneca (U.K.)

  • Johnson & Johnson Private Limited (U.S.)

  • Hikma Pharmaceuticals PLC (U.K.)

  • Reddy's Laboratories Ltd. (India)

  • Fresenius Kabi AG (Germany)


Laxatives Industry Developments


August 2019 The UAE Ministry of Health and Prevention issued a circular noting the withdrawal of the Laxocodyl suppositories batch used for treating constipation in adults, produced by JulpharGulf Pharmaceutical Industries, due to incorrect labeling.


March 2021 Avrio Health L.P., a Purdue Pharma L.P. company, announced two Senokot laxative products Senokot Laxative* Gummies and Senokot Laxative* Tea.


Laxatives Market Segmentation


Laxatives Route of Administration Outlook (USD Billion, 2018-2032)



  • Oral

  • Rectal


Laxatives Indication Outlook (USD Billion, 2018-2032)



Laxatives Drug Type Outlook



  • Hyperosmotic

  • Bulk-Forming

  • Stool Softeners

  • Lubricants

  • Stimulants


Laxatives End User Outlook



  • Hospitals & Clinics

  • Research Institutes

  • Others


Laxatives Regional Outlook



  • North America

    • US

    • Canada



  • Europe

    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Rest of Europe



  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Australia

    • Rest of Asia-Pacific



  • Rest of the World

    • Middle East

    • Africa

    • Latin America



Report Scope:

Laxatives Report Scope
Report Attribute/Metric Details
Market Size 2022 USD 6.5 Billion
Market Size 2023 USD 6.89 Billion
Market Size 2032 USD 10.98 Billion
Compound Annual Growth Rate (CAGR) 6.00% (2023-2032)
Base Year 2022
Market Forecast Period 2023-2032
Historical Data 2018- 2022
Market Forecast Units Value (USD Billion)
Report Coverage Revenue Forecast, Growth Factors, Market Competitive Landscape, and Trends
Segments Covered Route of Administration, Indication, Drug Type, End User and Region
Geographies Covered North America, Europe, Asia Pacific, and the Rest of the World
Countries Covered The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
Key Companies Profiled F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Ireland), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), AstraZeneca (U.K.), and Johnson & Johnson Private Limited (U.S.)
Key Market Opportunities Increase in the number of research and development activities   
Key Market Dynamics Increasing investment in healthcare infrastructure




Frequently Asked Questions (FAQ) :

The  laxatives market size was valued at USD 6.5 Billion in 2022.

The  market is projected to grow at a CAGR of 6.00% during the forecast period, 2023-2032.

North America had the largest share of the  market

The key players in the market are Pfizer Inc. (U.S.), Sanofi (France), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), AstraZeneca (U.K.), and Johnson & Johnson Private Limited (U.S.).

The oral category dominated the market in 2022.

Chronic constipation had the largest share in the market.

The lubricants category dominated the market in 2022.

The research institutes had the largest share of the market.

Key Questions Answered

  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Request Free Sample

Why Choose Market Research Future?

  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.
Speak to Analyst
Leading companies partner with us for data-driven Insights.
Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response
Invalid